Synchron
PrivateLast Round
Series D
Nov 6, 2025
Est. Valuation
$1B
Total Funding Raised
$335M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Synchron operates in Healthcare & Life Sciences and is based in Brooklyn, New York. Its latest recorded funding round was a Series D round in November 2025.
Synchron is a neurotechnology company that develops implantable, minimally invasive brain-computer interfaces designed to interpret brain signals for treating conditions like paralysis.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Application
Price History
Caplight MarketPrice™ estimate for Synchron, published with a 90-day delay.
Caplight MarketPrice™
$47.17
per share, as of July 2026
+27.2%
10-month change
The most recent months of MarketPrice™ are available to Caplight clients.
Caplight MarketPrice™ is an estimate of private secondary market pricing, shown here on a delayed basis for illustrative purposes only. It may be incomplete, is subject to change, and may not be relied upon for any purpose or considered investment advice.
Synchron Comparables
Compare Synchron with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Precision Neuroscience | 88% | |
| Neuralink | 86% | |
| Paradromics | 78% |
For institutional investors. Book with your work email.
Synchron Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Nov 6, 2025 | ||||
| Series C | Dec 15, 2022 | ||||
| Grant | Aug 26, 2021 | ||||
| Series B | Jun 3, 2021 | ||||
| Series A | Apr 4, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Synchron Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forepont Capital Partners | Series B, Series C |
| Greenoaks Capital Partners | Series C |
| Khosla Ventures | Series C, Series D, Series B |
| U.S. Department of Defense | Series A |
| Bezos Expeditions | Series C, Series D |
| re.Mind Capital | Series B |
| T.Rx Capital | Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 12, 2026
Brain implant trials halted due to unspecified performance issues.
- May 3, 2026
Company scales to approximately 100 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 12, 2026
Synchron, Inc. is actively developing a successor BCI device aimed at restoring communication and mobility for individuals with severe paralysis while it addresses performance issues in its current implant.
- has_issues_withNov 12, 2026
Synchron, Inc. has a performance problem with the lead connecting its Stentrode implant to under-skin electronics and voluntarily pauses enrollment in the United States, Australia and Canada on Nov 12th '26; it says the Stentrode itself is unaffected, identifies no device-related safety issues, and plans to upgrade the hardware before recruitment restarts, with no restart date set.
For institutional investors. Book with your work email.
Synchron Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Synchron's valuation, stock price, and market status.
Is Synchron a public or private company?
Synchron is a private company.
What is the current stock price of Synchron?
Synchron is a private company, so its shares have no public market price. Caplight tracks Synchron's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Synchron worth (valuation)?
Synchron's valuation is estimated at $1.0B based on funding round data.
Can I buy Synchron stock?
Synchron shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Synchron's last funding round?
Synchron's most recent funding round was Series D on November 6, 2025.
Who are the main investors in Synchron?
Key investors in Synchron include Khosla Ventures, ARCH Venture Partners, NeuroTechnology Investors, Double Point Ventures.
Will Synchron IPO soon?
No public IPO plans have been announced for Synchron.
How can I track Synchron secondary market activity?
Caplight tracks bids, offers, and trades in Synchron's shares on secondary markets.